Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Cash from Financing Activities (2016 - 2022)

Edesa Biotech's Cash from Financing Activities history spans 8 years, with the latest figure at -$286.0 for Q3 2022.

  • For Q3 2022, Cash from Financing Activities fell 100.13% year-over-year to -$286.0; the TTM value through Sep 2022 reached $11.6 million, down 17.96%, while the annual FY2025 figure was $17.0 million, 2776.69% up from the prior year.
  • Cash from Financing Activities for Q3 2022 was -$286.0 at Edesa Biotech, down from $10.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $11.9 million in Q1 2021 and bottomed at -$27494.0 in Q2 2020.
  • The 4-year median for Cash from Financing Activities is $1.2 million (2021), against an average of $3.0 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 4333.27% in 2020 before it tumbled 100.13% in 2022.
  • A 4-year view of Cash from Financing Activities shows it stood at $45000.0 in 2019, then surged by 4333.27% to $2.0 million in 2020, then tumbled by 38.42% to $1.2 million in 2021, then tumbled by 100.02% to -$286.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Cash from Financing Activities are -$286.0 (Q3 2022), $10.4 million (Q1 2022), and $1.2 million (Q4 2021).